A CME Satellite Symposium held at the Virtual Annual Scientific Meeting of the Heart Failure Society of America

HFrEF: Challenges, Unmet Needs and Emerging Therapies

Friday, October 2, 2020 | 4:30 - 5:45 pm EDT

Symposium Agenda

4:30 PM  Introduction and Brief Overview of HFrEF
  • Justin A. Ezekowitz

4:35 PM  Does it matter when we change a medication?
  • Nancy Sweitzer

4:50 PM  What to do when the kidneys and the heart misbehave together?
  • Clara Saldarriaga

5:05 PM  Many drugs at a low dose, or one-two drugs at a high dose?
  • Finlay McAlister

5:20 PM  Coloring in between the EF lines
  • Carolyn S.P. Lam

5:35 PM  Panel Discussion and Audience Q&A
  • All Faculty

5:45 PM  Adjourn

Learning Objectives

Following this activity, participants will be able to:

• Define the problem of HFrEF within the broader heart failure population.
• Discuss the rationale for medication changes and the impact of the timing for medication adjustments.
• Identify the mechanism of action for current therapies targeted toward patients with HFrEF, and the importance of balancing cardiorenal benefits.
• Describe data from recent clinical trials outlining possible treatments and potential patients who would benefit.
• Identify challenges and possible barriers to treatment, including compliance, quality of life concerns, disease severity, financial burden, and potential outcomes.

Program Chair

Justin A. Ezekowitz, MBCh, MSc
Professor of Medicine,
Division of Cardiology,
University of Alberta
Cardiologist, Mazankowski
Alberta Heart Institute
Co-Director, Canadian VIGOUR Centre
Edmonton, Alberta, Canada

Faculty (cont’d)

Clara Saldarriaga, MD
Associate Professor
University of Antioquia
Department of Cardiology
Clinica CardioVID
Medellin, Colombia

Finlay McAlister, MD, MSc
General Internist, University of Alberta Hospital
Professor, Division of General Internal Medicine and Heart Function Clinic,
University of Alberta
Scientific Director, Alberta SPOR (Support for Patient Oriented Research) Support Unit
Alberta Health Services Chair in Cardiovascular Outcomes Research
Edmonton, Alberta, Canada

Carolyn S.P. Lam, MBBS, PhD, FRCP
Senior Consultant Cardiologist,
National Heart Centre Singapore
Professor, Duke-NUS Medical School
Singapore

Faculty

Nancy Sweitzer, MD, PhD
Chief of Cardiology
Director, Sarver Heart Center
University of Arizona
Editor-in-Chief, Circulation: Heart Failure, Tuscon, AZ

ACCREDITATION

Physicians:
Accreditation Statement: In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The Heart Failure Society of America designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses:
This educational activity is approved for continuing nursing education (CNE) units by the HFSA, an accredited provider of the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity is approved for a maximum of 1.25 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.

ELIGIBILITY

Registration for the HFSA Virtual Annual Scientific Meeting is required to attend this symposium.

Supported by an independent medical education grant from Merck.

This satellite symposium is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.